Idera Pharmaceuticals, Inc. (IDRA)
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States.
It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer.
The company has a collaboration and supply agreement with AbbVie Inc. and Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.
|IPO Date||Jan 24, 1996|
505 Eagleview Blvd Ste 212
Exton, Pennsylvania 19341-1199
|Phone||484 348 1600|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Vincent J. Milano||President, Chief Executive Officer and Director|
|John J. Kirby||Senior Vice President and Chief Financial Officer|
|Bryant David Lim||Senior Vice President, General Counsel and Corporate Secretary|
|Robert Clayton Fletcher||Consultant|
|Daniel B. Soland||Senior Vice President and Chief Operating Officer|
|Jill Conwell||Senior Vice President of Investor Relations and Corporate Communications|
|Elizabeth Eberhardt||Senior Vice President of Product Leadership|
|Dr. Shah Rahimian M.D., Ph.D.||Medical Director and Global Clinical Lead for Oncology|
|Dr. Joanna C. Horobin Ch.B, M.B.||Advisor|
|Dr. Sudhir Agrawal||Scientific Advisor|